NDC 17856-0353-2 - Pharbetol Regular strength
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 17856-0353
- Requested NDC
- 17856-0353-2
- Package NDCs from labels
- 17856-0353-2, 17856-0353-1, 17856-0353-4, 17856-0353-3
- Manufacturer
- ATLANTIC BIOLOGICALS CORP.
- Effective date
- 2025-06-05
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| PHARBEST IBUPROFEN Drug Facts | ATLANTIC BIOLOGICALS CORP. | 2025-06-05 | HUMAN OTC DRUG LABEL |
| Pharbetol Regular strength - ATLANTIC BIOLOGICALS CORP. | UNIT DOSE SOLUTIONS | ATLANTIC BIOLOGICALS CORP. | UNIT DOSE SOLUTIONS | 2024-04-30 | HUMAN OTC DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 17856-0353-1 | 2024-06-26 | C162847 | 48780-1 | 1030e365-250f-111a-e063-dadaa90a10e2 | PHARBEST IBUPROFEN Drug Facts |
| 17856-0353-1 | 2024-01-30 | C162847 | 48780-1 | 1030e365-250f-111a-e063-dadaa90a10e2 | PHARBEST IBUPROFEN Drug Facts |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 17856-0353-1 | PharbetolRegular strength | 100 in 1 BOX, UNIT-DOSE | TABLET | 100 | 3 | |
| 17856-0353-2 | PharbetolRegular strength | 1 in 1 POUCH | TABLET | 1 | 3 | |
| 17856-0353-4 | PharbetolRegular strength | 24 in 1 BOTTLE | TABLET | 24 | 3 | |
| 17856-0353-3 | PharbetolRegular strength | 28 in 1 BOTTLE | TABLET | 28 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 17856-0353 | PHARBETOL REGULAR STRENGTH (ACETAMINOPHEN) TABLET [ATLANTIC BIOLOGICALS CORP.] | 2 | Current NDC, Legacy NDC, 3 package rows | 20240627_05a91d24-b498-4ba2-a275-68b871cf62d2.zip |
| 17856-0353 | PHARBETOL REGULAR STRENGTH (ACETAMINOPHEN) TABLET [ATLANTIC BIOLOGICALS CORP.] | 1 | Current NDC, Legacy NDC, 1 package rows | 20240508_bd26081c-e81e-42e8-b3da-2813863a51df.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sinus Severe | ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | AmeriSource Bergen | 3dc293c9-736b-4bd8-b993-ff83b9909bcd | 2024-02-23 | Warnings | 362O9ITL9D |
| Pain Reliever PM Extra Strength | ACETAMINOPHEN, DIPHENHYDRAMINE HCL | BJWC (Berkley & Jensen / BJ's) | b20a08f3-c9c0-4bd9-8ce0-acb932b5bb86 | 2024-02-22 | Warnings | M013 362O9ITL9D |
| Butalbital, Acetaminophen, and Caffeine | BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE | LGM PHARMA SOLUTIONS, LLC | f6548126-faa1-4f53-8e0b-bc1b743de04d | 2024-02-21 | Boxed warning, Warnings, Adverse reactions | 362O9ITL9D |
| Basic Care Dual Action | ACETAMINOPHEN, IBUPROFEN | Amazon.com Services LLC | 7e27f5cb-8728-400f-82c5-0984276aa5dd | 2024-02-20 | Warnings | 362O9ITL9D |
| M-PAP | ACETAMINOPHEN | Bryant Ranch Prepack | 31a41976-7f65-42d7-acf5-de9c2c5ca58e | 2024-02-20 | Warnings | M013 362O9ITL9D |
| Publix Fast Relief Effervescent - Original Flavor | ASPIRIN | PUBLIX SUPER MARKETS INC. | 0a342f72-45fd-3e12-e063-6394a90ae33e | 2024-02-16 | Warnings | M013 |
| Equaline Effervescent Pain Reliever | ASPIRIN | UNITED NATURAL FOODS, INC. DBA UNFI | 0761299a-e913-7665-e063-6394a90a6003 | 2024-02-16 | Warnings | M013 |
| TopCare Effervescent Pain Relief | ASPIRIN | TOPCO ASSOCIATES LLC | 075f36e1-110c-e839-e063-6294a90a89d7 | 2024-02-16 | Warnings | M013 |
| Butalbital, Acetaminophen and Caffeine | BUTALBITAL, ACETAMINOPHEN AND CAFFEINE | KVK-Tech, Inc. | 7f9c4668-4f4a-453b-b2fa-a6fed903ddfa | 2024-02-16 | Boxed warning, Warnings, Adverse reactions | 362O9ITL9D |
| HYDROCORTISONE | HYDROCORTISONE ACETATE | HART Health | 779f945f-ab69-40de-8d86-ab76debc5c7c | 2024-02-16 | Warnings | M |
| First Aid and Burn | BENZALKONIUM CHLORIDE, LIDOCAINE | HART Health | f5746bba-9d7f-4691-b466-14985473bf14 | 2024-02-16 | Warnings | M |
| Butalbital, Acetaminophen, Caffeine | BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE | A-S Medication Solutions | f822c103-b678-4e76-8174-33b94421dd1e | 2024-02-15 | Boxed warning, Warnings, Adverse reactions | 362O9ITL9D |
| Hydrocodone Bitartrate and Acetaminophen | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | Lupin Pharmaceuticals,Inc. | 48cc1378-ffab-4645-95bb-a05d78066575 | 2024-02-15 | Boxed warning, Warnings, Adverse reactions | 362O9ITL9D |
| Extra Strength Pain Reliever | ACETAMINOPHEN | INGLES MARKETS, INC. | 115d0b4f-6f0f-79a9-e063-6394a90ab18a | 2024-02-14 | Warnings | M013 362O9ITL9D |
| Allergy Sinus, Lil Drug Store | ACETAMINOPHEN, PHENYLEPHRINE HYDROCHLORIDE, CHLORPHENIRAMINE MALEATE | Lil' Drug Store Products, Inc. | 1145440e-b37a-6e5e-e063-6294a90ab4a0 | 2024-02-13 | Warnings | 362O9ITL9D |
| Theraflu ExpressMax Daytime Severe Cold and Cough | ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL | Haleon US Holdings LLC | ff48b55a-0d32-47d6-941d-d99c7cf52f94 | 2024-02-12 | Warnings | 362O9ITL9D |
| OXYCODONE AND ACETAMINOPHEN | OXYCODONE AND ACETAMINOPHEN | XLCare Pharmaceuticals, Inc. | 7f3c6dd7-6bc8-450e-aded-997f9cf63a8f | 2024-02-12 | Boxed warning, Warnings, Adverse reactions | 362O9ITL9D |
| PANADOL | ACETAMINOPHEN | Haleon US Holdings LLC | e1799765-c247-42b4-ad6a-8ba7d136abf2 | 2024-02-06 | Warnings | M013 362O9ITL9D |
| Panadol Cold and Flu NonDrowsy | ACETAMINOPHEN AND PHENYLEPRINE HCL | Haleon US Holdings LLC | f626ab17-01c9-4493-ba9e-0c8c11146384 | 2024-02-06 | Warnings | M013 362O9ITL9D |
| PANADOL Extra | ACETAMINOPHEN AND CAFFEINE | Haleon US Holdings LLC | e5c2d88a-d903-4ca0-b895-f27e791dfc4e | 2024-02-06 | Warnings | M013 362O9ITL9D |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.